208 related articles for article (PubMed ID: 17336978)
21. Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity.
Vicennati V; Ceroni L; Genghini S; Patton L; Pagotto U; Pasquali R
Obesity (Silver Spring); 2006 Feb; 14(2):235-43. PubMed ID: 16571848
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome.
Lanzone A; Fulghesu AM; Guido M; Cucinelli F; Caruso A; Mancuso S
Fertil Steril; 1997 Jan; 67(1):34-9. PubMed ID: 8986680
[TBL] [Abstract][Full Text] [Related]
23. Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome.
Kjøtrød SB; Sunde A; von Düring V; Carlsen SM
Fertil Steril; 2009 Feb; 91(2):500-8. PubMed ID: 18304542
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study.
Romualdi D; Costantini B; Campagna G; Lanzone A; Guido M
Fertil Steril; 2008 Nov; 90(5):1826-33. PubMed ID: 18166189
[TBL] [Abstract][Full Text] [Related]
25. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
26. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome.
Carmina E; Gonzalez F; Chang L; Lobo RA
Obstet Gynecol; 1995 Jun; 85(6):971-6. PubMed ID: 7770269
[TBL] [Abstract][Full Text] [Related]
27. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome.
Bahceci M; Aydemir M; Tuzcu A
Fertil Steril; 2007 Jun; 87(6):1363-8. PubMed ID: 17362944
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of ovarian and adrenal sources of androgens in women with polycystic ovary syndrome. Dexamethasone and GnRH-agonist administration.
Fulghesu AM; Lanzone A; Fortini A; Guido M; Caruso A; Mancuso S
J Reprod Med; 1993 May; 38(5):387-92. PubMed ID: 8320677
[TBL] [Abstract][Full Text] [Related]
29. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Romualdi D; Guido M; Ciampelli M; Giuliani M; Leoni F; Perri C; Lanzone A
Hum Reprod; 2003 Jun; 18(6):1210-8. PubMed ID: 12773448
[TBL] [Abstract][Full Text] [Related]
30. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.
Guido M; Romualdi D; Suriano R; Giuliani M; Costantini B; Apa R; Lanzone A
Hum Reprod; 2004 Mar; 19(3):534-9. PubMed ID: 14998947
[TBL] [Abstract][Full Text] [Related]
31. Plasma adrenomedullin levels in patients with polycystic ovary syndrome.
Ucar B; Noyan V; Caglayan O; Yucel A; Sagsoz N
Fertil Steril; 2006 Oct; 86(4):942-8. PubMed ID: 16963041
[TBL] [Abstract][Full Text] [Related]
32. A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome.
Glintborg D; Hermann AP; Hagen C; Jensen LT; Frystyk J; Bennett P; Flyvbjerg A; Andersen M
Fertil Steril; 2009 Mar; 91(3):842-50. PubMed ID: 18402944
[TBL] [Abstract][Full Text] [Related]
33. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
Arslanian SA; Lewy V; Danadian K; Saad R
J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
[TBL] [Abstract][Full Text] [Related]
34. Effects of different treatments for hyperthyroidism on the hypothalamic-pituitary-adrenal axis.
Lizcano F; Salvador J
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1085-90. PubMed ID: 18505442
[TBL] [Abstract][Full Text] [Related]
35. Increased adrenal steroid secretion in response to CRF in women with hypothalamic amenorrhea.
Genazzani AD; Bersi C; Luisi S; Fruzzetti F; Malavasi B; Luisi M; Petraglia F; Genazzani AR
J Steroid Biochem Mol Biol; 2001 Sep; 78(3):247-52. PubMed ID: 11595505
[TBL] [Abstract][Full Text] [Related]
36. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
Glintborg D; Højlund K; Andersen M; Henriksen JE; Beck-Nielsen H; Handberg A
Diabetes Care; 2008 Feb; 31(2):328-34. PubMed ID: 18000176
[TBL] [Abstract][Full Text] [Related]
37. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome.
Genazzani AD; Strucchi C; Luisi M; Casarosa E; Lanzoni C; Baraldi E; Ricchieri F; Mehmeti H; Genazzani AR
Gynecol Endocrinol; 2006 Jan; 22(1):36-43. PubMed ID: 16522532
[TBL] [Abstract][Full Text] [Related]
38. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
[TBL] [Abstract][Full Text] [Related]
39. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
Azziz R; Ehrmann DA; Legro RS; Fereshetian AG; O'Keefe M; Ghazzi MN;
Fertil Steril; 2003 Apr; 79(4):932-7. PubMed ID: 12749433
[TBL] [Abstract][Full Text] [Related]
40. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
